**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9901599-2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| (51) International Patent Classification 6 : A61K 31/70 | A2 | (11) International Publication Number: WO 98/18477 |
|---|---|---|
| | | (43) International Publication Date: 7 May 1998 (07.05.98) |

(21) International Application Number: PCT/EP97/05953

(22) International Filing Date: 29 October 1997 (29.10.97)

(30) Priority Data:
9622681.6 31 October 1996 (31.10.96) GB

(71) Applicant *(for all designated States except US)*: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GOODSON, Gary, Wayne [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). WOOD, Allen, Wayne [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). FORD, Katherine, Jeannette [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).

(74) Agent: QUILLIN, Helen, K.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

**Published**
*Without international search report and to be republished upon receipt of that report.*

(54) Title: PHARMACEUTICAL COMPOSITIONS CONTAINING LAMIVUDINE AND ZIDOVUDINE

(57) Abstract

A pharmaceutical composition and a method of inhibiting human immunodeficiency virus (HIV) is disclosed which comprises administering to an HIV infected patient a homogenous combination of lamivudine, zidovudine and a pharmaceutical glidant in an amount which achieves antiviral efficacy.